Stocktoria
ARROWHEAD PHARMACEUTICALS, INC. ARWR
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $829.4M at a -0.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-06 | HC Wainwright & Co. | Buy (main) |
| 2026-07-30 | B. Riley Securities | Buy (main) |
| 2026-07-27 | HC Wainwright & Co. | Buy (main) |
| 2026-07-23 | Morgan Stanley | Overweight (main) |
| 2026-07-23 | Piper Sandler | Overweight (reit) |
| 2026-07-22 | Chardan Capital | Buy (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.545 |
| Retained earnings / assets | -1.175 |
| EBIT / assets | 0.071 |
| Equity / liabilities | 0.571 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ARWR | ARROWHEAD PHARMACEUTICALS, INC. | 4/9 | 0.82 | — | — |
| HRMY | Harmony Biosciences Holdings, Inc. | 5/9 | 7.17 | 12.9 | +21.5% |
| COLL | COLLEGIUM PHARMACEUTICAL, INC | 6/9 | 1.76 | 18.9 | +23.6% |
| ANIP | ANI PHARMACEUTICALS INC | 6/9 | 3.26 | 24.5 | +43.8% |
| CORT | CORCEPT THERAPEUTICS INC | 4/9 | 8.97 | 94.1 | +12.8% |
| EBS | Emergent BioSolutions Inc. | 6/9 | 3.44 | 8.4 | -28.8% |
| PCRX | Pacira BioSciences, Inc. | 8/9 | 3.08 | 141.1 | +3.6% |
About ARROWHEAD PHARMACEUTICALS, INC.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
FAQ
Is ARWR financially healthy?
ARROWHEAD PHARMACEUTICALS, INC.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does ARWR pay a dividend?
No, ARROWHEAD PHARMACEUTICALS, INC. does not currently pay a dividend.
How profitable is ARWR?
In FY2025, ARROWHEAD PHARMACEUTICALS, INC. had a net margin of -0.2% and a return on equity of -0.3%.
What is the analyst price target for ARWR?
The average Wall-Street price target for ARROWHEAD PHARMACEUTICALS, INC. is $110.18, about 26.3% above the recent price, from 11 analysts (consensus: strong buy).
Is ARWR a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on ARROWHEAD PHARMACEUTICALS, INC.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-09-30. Facts plus Stocktoria's own computed scores — not investment advice.